MMV183

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Potential for use in severe malaria
MoA
  • Inhibition of acetylCoA synthetase (acetylCS)
  • No pre-existing resistance, no resistance in vitro
Key features
  • Novel mechanism of action
  •  
    Predicted human efficacious dose = 100 mg single dose
  •  
    High solubility and good overall physical properties
  •  
    Transmission-blocking activity
Challenges
  • Challenge to define safety margins, as exposure decreases strongly after the second dose in all tox species tested
Status
  • Preclinical development
Next milestone
  • Conduct Good Laboratory Practice (GLP) toxicology and safety pharmacology program
  •  
    Optimization of synthesis route and formulation
Previously
  • From a discovery collaboration with TropIQ
MMV Project Director
  • Ilaria Di Resta